Balanced news tone
News Sentiment
VERX sentiment intelligence
Vertex news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+3.4% over one week, +15.1% over four weeks, trend inactive, and below fair value.
Vertex, Inc. Stock 12‑Month Price Target Cut to $17.69, Implies 37% Upside
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Vertex, Inc. Stock 12‑Month Price Target Cut to $17.69, Implies 37% Upside
- Tone
- Negative 35/100
- Event
- Analyst action
- Published
- 21 Jul 2026 22:20
- Source
- TradingView
Vertex (NASDAQ:VERX) Shares Gap Down - Time to Sell?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 21 Jul 2026 15:55
- Source
- MarketBeat
Vertex Facing Uncertain Growth Path Amid AI Fears, Morgan Stanley Says
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 21 Jul 2026 15:06
- Source
- MT Newswires
Correction: Morgan Stanley Downgrades Vertex to Equalweight From Overweight Adjusts PT to $15 From $19
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 21 Jul 2026 10:24
- Source
- MT Newswires
Morgan Stanley Downgrades Vertex to Equalweight From Overweight, Cuts Price Target to $15 From $19
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 21 Jul 2026 10:21
- Source
- MT Newswires
Vertex Pharma stock trades near record levels as cystic fibrosis franchise drives earnings growth
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 21 Jul 2026 02:41
- Source
- Ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 21 Jul 2026 00:47
- Source
- simplywall.st
Vertex Pharma stock trades near highs as cystic fibrosis portfolio drives double digit revenue growt
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 20 Jul 2026 14:14
- Source
- Ad-hoc-news.de
Vertex schedules 5 p.m. call on Aug. 3 to discuss results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:30
- Source
- Stock Titan
Vertex to Announce Second Quarter 2026 Financial Results on Monday, August 3, 2026
Vertex, Inc. (NASDAQ:VERX) announced that it will release its second quarter 2026 financial results after market close on Monday, August 3, 2026. A conference call to discuss these results will be held at 5:00 p.m. Eastern Time on the same day. Investors can register for the live
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 12:40
- Source
- Sahm
Enterprise value to EBIT forward of Vertex, Inc. Class A – LS:A2P93F
This article focuses on the "Enterprise value to EBIT forward" metric for Vertex, Inc. Class A, identified by the stock symbol A2P93F on the Lang & Schwarz Tradecenter. The piece is primarily a financial data point from TradingView, indicating a specific valuation ratio for the c
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 11:10
- Source
- TradingView
Enterprise value to EBIT forward of Vertex, Inc. Class A – LSX:A2P93F
This article displays the enterprise value to EBIT forward for Vertex, Inc. Class A (LSX:A2P93F) on TradingView. It provides a brief financial metric for the company, accessible through the platform's various financial tools and data services.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 10:10
- Source
- TradingView
Vertex Inc (VERX) Shares Fall 3.2% -- What GF Score of 61 Tells Investors
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 10 Jul 2026 22:58
- Source
- GuruFocus
Understanding Momentum Shifts in (VERX)
This article provides an analysis of Vertex Inc. (VERX) stock, highlighting strong near and mid-term sentiment but a weak long-term outlook. It presents AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, a
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 10 Jul 2026 16:04
- Source
- Stock Traders Daily
TD Cowen Rates Vertex (VERX) A Buy; Sees Sentiment Improving On Execution
- Tone
- Positive 66/100
- Event
- Macro sensitivity
- Published
- 05 Jul 2026 07:00
- Source
- Market source
Why Vertex Stock Is Rising Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 16:21
- Source
- Motley Fool
TD Cowen Initiates Vertex at Buy With $14 Price Target
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 29 Jun 2026 10:56
- Source
- MT Newswires
Vertex Pharma enters Russell 1000 value, shares reflect mixed benchmark shift
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 08:39
- Source
- Ad-hoc-news.de
Vertex, Inc. Class A Actuals & Estimates (NASDAQ:VERX)
This article provides current financial data and analyst estimates for Vertex, Inc. (VERX), a company traded on NASDAQ. It covers stock performance, price targets, earnings, revenue, market capitalization, and volatility, along with answers to frequently asked questions about the
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 26 Jun 2026 13:09
- Source
- TradingView
Price to earnings forward of Vertex, Inc. Class A – FWB:56X
This page from TradingView provides financial information for Vertex, Inc. Class A (FWB:56X) on the Frankfurt Stock Exchange, specifically focusing on its Price to Earnings Forward metric. The content highlights the stock's overview, financials, news, and community discussions. I
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 00:41
- Source
- TradingView
Vertex, Inc. Class A Actuals & Estimates (MUN:56X)
This article provides actuals and estimates for Vertex, Inc. Class A (MUN:56X), detailing its financial performance, analyst forecasts, and key company data. It includes information on past earnings, revenue, net income, and upcoming earnings reports, along with historical stock
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 23:41
- Source
- TradingView
Vertex Pharma Stock (US92532F1003): Analyst sentiment and ownership moves keep VRTX in focus
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 14 Jun 2026 07:00
- Source
- Ad-hoc-news.de
Vertex (VERX) director Philip Saunders receives 15,638 restricted shares in equity grant
Vertex, Inc. director Philip Seth Saunders received an equity grant of 15,638 shares of Class A Common Stock as restricted stock, with no cash purchase price. This grant increases his direct holdings to 50,606 shares. The restricted shares will vest on the earlier of the day imme
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 13 Jun 2026 12:39
- Source
- Stock Titan
Vertex (NASDAQ: VERX) director granted 15,638 restricted shares
Vertex, Inc. director Gayton Bradley M was granted 15,638 restricted shares of Class A Common Stock at no cash cost per share, increasing his direct holdings to 68,500 shares. The restricted stock award vests on the earlier of the day before the company's next annual stockholder
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 13 Jun 2026 12:09
- Source
- Stock Titan
Vertex (NASDAQ: VERX) director granted 15,638 shares of restricted stock
Vertex, Inc. director John Richard Stamm was granted 15,638 shares of Class A Common Stock as restricted stock, which is considered equity compensation. These shares, valued at $0.00 per share for the grant, will vest on the earlier of the day before Vertex’s next annual stockhol
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jun 2026 12:09
- Source
- Stock Titan
Director Eric C. Andersen awarded 15,638 Vertex (VERX) restricted shares
Vertex, Inc. director Eric C. Andersen was granted 15,638 shares of Class A common stock as restricted stock, with no cash cost. This award will vest on the earlier of the day before the next annual stockholders’ meeting or June 10, 2027. Following this grant, Andersen directly h
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 12 Jun 2026 20:38
- Source
- Stock Titan
Vertex (VERX) director Westphal awarded 15,638 restricted shares
Vertex, Inc. director and ten percent owner Amanda Westphal was awarded 15,638 restricted shares of Class A Common Stock at no purchase price. These shares will vest on the earlier of the day before the next annual stockholder meeting or June 10, 2027. Following this grant, Westp
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 20:38
- Source
- Stock Titan
Vertex (VERX) director granted 15,638 restricted shares, total holdings now 20,965
Vertex, Inc. director Mark J. Mendola was granted 15,638 restricted shares of Class A Common Stock as a compensation-related award, bringing his total direct holdings to 20,965 shares. The shares were awarded at no cash cost and will vest on the earlier of the day before the comp
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 12 Jun 2026 20:38
- Source
- Stock Titan
Vertex (VERX) director DeStefano granted 15,638 restricted Class A shares
Vertex, Inc. director David DeStefano was granted 15,638 Class A Common Stock shares as restricted stock, with a stated price of $0.00 per share. This award is compensation-related and will vest on the earlier of the next annual stockholders' meeting or June 10, 2027. Following t
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 20:38
- Source
- Stock Titan
VERX SEC Filings - Vertex, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Vertex, Inc. (VERX) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. It highlights recent filings detailing BlackRock's stake in Vertex, credit agreement amendments for shareholder returns, a CEO
- Tone
- Positive 58/100
- Event
- Deals and strategy
- Published
- 12 Jun 2026 18:38
- Source
- Stock Titan